Billiontoone, Inc.'s Lock-Up Period To Expire on May 5th (NASDAQ:BLLN)

Key Points

• Lock-up period expires May 5: On May 5 insiders and major shareholders will be free to sell shares from the 4,551,100‑share IPO (initial price $60), potentially increasing selling pressure.
• Strong recent results: BillionToOne reported $0.11 EPS vs. $0.04 expected and revenue of $96.05M (up 113% year‑over‑year), showing rapid top‑line growth despite a high trailing P/E.
• Analyst view mixed but positive on average: The consensus rating is a "Moderate Buy" with an average target of $126.71, although several firms have recently trimmed price targets and ratings range from buy to sell.

Billiontoone's (NASDAQ:BLLN - Get Free Report) lock-up period is set to expire on Tuesday, May 5th. Billiontoone had issued 4,551,100 shares in its initial public offering on November 6th. The total size of the offering was $273,066,000 based on an initial share price of $60.00. After the expiration of Billiontoone's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

BLLN has been the topic of a number of recent research reports. Wall Street Zen raised Billiontoone from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. BTIG Research cut their target price on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. Guggenheim cut their target price on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Wells Fargo & Company cut their target price on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Finally, Weiss Ratings assumed coverage on Billiontoone in a research note on Tuesday, February 3rd. They issued a "sell (d)" rating on the stock. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $126.71.

Billiontoone Price Performance

NASDAQ BLLN opened at $81.76 on Tuesday. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $3.76 billion and a PE ratio of 389.33. Billiontoone has a 1 year low of $61.96 and a 1 year high of $138.70. The business has a 50-day simple moving average of $78.36.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million during the quarter, compared to the consensus estimate of $85.85 million. Billiontoone's revenue was up 113.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Billiontoone will post 0.42 earnings per share for the current year.

Institutional Trading of Billiontoone

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wasatch Advisors LP purchased a new stake in Billiontoone in the first quarter worth about $29,179,000. Caitong International Asset Management Co. Ltd purchased a new stake in Billiontoone in the fourth quarter worth about $230,000. T. Rowe Price Investment Management Inc. purchased a new stake in Billiontoone in the fourth quarter worth about $8,277,000. Invesco Ltd. purchased a new stake in Billiontoone in the fourth quarter worth about $15,535,000. Finally, XTX Topco Ltd purchased a new stake in Billiontoone in the fourth quarter worth about $1,692,000.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.